{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:45:45Z","timestamp":1792691145833,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40257-020-00545-9","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T02:03:21Z","timestamp":1597629801000},"page":"725-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-350X","authenticated-orcid":false,"given":"Kathleen W.","family":"Wyrwich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-0794","authenticated-orcid":false,"given":"Helen","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-6184","authenticated-orcid":false,"given":"Sarah","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7431","authenticated-orcid":false,"given":"Natalie V. J.","family":"Aldhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-0438","authenticated-orcid":false,"given":"Jake","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8833-2223","authenticated-orcid":false,"given":"Fabio P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-1152","authenticated-orcid":false,"given":"Yves","family":"Dutronc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-7002","authenticated-orcid":false,"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4232-5906","authenticated-orcid":false,"given":"Justin M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"545_CR1","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. 2018. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm610442.pdf. Accessed Oct 2018."},{"issue":"2","key":"545_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","volume":"40","author":"E Olsen","year":"1999","unstructured":"Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol. 1999;40(2):242\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"545_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines\u2014part II. J Am Acad Dermatol. 2004;51(3):440\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"545_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/jidsymp.2015.45","volume":"17","author":"JA Solomon","year":"2015","unstructured":"Solomon JA. Development of uniform protocol for alopecia areata clinical trials. J Investig Dermatol Symp Proc. 2015;17(2):63\u20136.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"3","key":"545_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1529-8019.2011.01413.x","volume":"24","author":"AM Finner","year":"2011","unstructured":"Finner AM. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011;24(3):348\u201354.","journal-title":"Dermatol Ther"},{"issue":"4691","key":"545_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1136\/bmj.2.4691.1250","volume":"2","author":"I Anderson","year":"1950","unstructured":"Anderson I. Alopecia areata: a clinical study. BMJ. 1950;2(4691):1250\u20132.","journal-title":"BMJ"},{"key":"545_CR7","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes F, et al. A qualitative interview study to understand the psychosocial burden of alopecia areata. In: 28th congress of European academy of dermatology and venereology, Madrid, Spain; 9\u201313 Oct 2019."},{"issue":"7522","key":"545_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.331.7522.951","volume":"331","author":"N Hunt","year":"2005","unstructured":"Hunt N, McHale S. The psychological impact of alopecia. BMJ. 2005;331(7522):951\u20133.","journal-title":"BMJ"},{"issue":"3","key":"545_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1068\/p5027","volume":"32","author":"J Sadr","year":"2003","unstructured":"Sadr J, Jarudi I, Sinha P. The role of eyebrows in face recognition. Perception. 2003;32(3):285\u201393.","journal-title":"Perception"},{"issue":"7","key":"545_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/ijd.13866","volume":"57","author":"K Chelidze","year":"2018","unstructured":"Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57(7):776\u201383.","journal-title":"Int J Dermatol"},{"key":"545_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18883","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. The Alopecia Areata InvestigatorGlobal Assessment (AA-IGA\u2122) scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.18883.","journal-title":"Br J Dermatol"},{"key":"545_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19024","author":"K Wyrwich","year":"2020","unstructured":"Wyrwich K, Kitchen H, Knight S, Aldhouse N, Macey J, Nunes F, et al. Development of the scalp hair assessment Patient-Reported Outcome\u2122 (PRO) measure for alopecia areata. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.19024.","journal-title":"Br J Dermatol"},{"key":"545_CR13","unstructured":"Food and Drug Administration (FDA). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed June 2019."},{"issue":"8","key":"545_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"key":"545_CR15","volume-title":"Cognitive interviewing: a tool for improving questionnaire design","author":"GB Willis","year":"2004","unstructured":"Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Thousand Oaks: Sage Publications; 2004."},{"issue":"2","key":"545_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"545_CR17","volume-title":"Applied thematic analysis","author":"G Guest","year":"2011","unstructured":"Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: Sage Publications; 2011."},{"issue":"9","key":"545_CR18","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep"},{"issue":"7","key":"545_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment (COA) instrument development. Value Health. 2018;21(7):839\u201342.","journal-title":"Value Health"},{"key":"545_CR20","volume-title":"Qualitative research practice: a guide for social science students and researchers","author":"J Ritchie","year":"2013","unstructured":"Ritchie J, Lewis J, Nicholls CM, Ormston R. Qualitative research practice: a guide for social science students and researchers. Thousand Oaks: Sage Publications; 2013."},{"issue":"1","key":"545_CR21","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/jidsymp.2013.30","volume":"16","author":"GS Ahluwalia","year":"2013","unstructured":"Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. J Investig Dermatol Symp Proc. 2013;16(1):S73\u2013S7676.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"545_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/DSS.0000000000000754","volume":"42","author":"J Carruthers","year":"2016","unstructured":"Carruthers J, Beer K, Carruthers A, Coleman WP III, Draelos ZD, Jones D, et al. Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis. Dermatol Surg. 2016;42(5):608\u201317.","journal-title":"Dermatol Surg"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00545-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:28:02Z","timestamp":1629142082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00545-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00545-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"17 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Helen Kitchen, Sarah Knight, Natalie V.J. Aldhouse, and Jake Macey are employees of DRG Abacus, a health economic and outcomes research consultancy that consults with various pharmaceutical companies. Kathleen W. Wyrwich was an employee and stockholder at Eli Lilly and Company when this research was conducted; she is now an employee and stockholder at Pfizer Inc. Fabio P. Nunes, and Yves Dutronc are employees and stockholders at Eli Lilly and Company. Dr. Brett King has served on advisory boards and is a consultant and clinical trial investigator for Eli Lilly and Company; he has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator for Aclaris Therapeutics Inc, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc and Pfizer Inc. Natasha Mesinkovska has no potential conflicts of interest. Eli Lilly and Company have commissioned DRG Abacus, Dr. Justin M. Ko and Dr. Brett A. King to consult on clinical outcomes assessment strategies for AA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The interview guides and methodology for this study were approved by the Human Research Ethics Committee Western Institutional Review Board (ref #20171820).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study. The photographs used in the photoguide were obtained separately from this study and its ethics committee approval; however, consent and release was obtained from patients to disclose their photographs.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}